Tag Archive for: Darzalex

The Latest in Myeloma Research: Updates From ASH 2021

The Latest in Myeloma Research: Updates from ASH 2021 from Patient Empowerment Network on Vimeo.

Myeloma specialist, Dr. Omar Nadeem, shares promising research advances in myeloma from the 2021 American Society of Hematology (ASH) annual meeting. Dr. Nadeem discusses the future of personalized medicine for myeloma, as well as positive results from a clinical study on quadruplet therapy.

Dr. Omar Nadeem is the Clinical Director of Myeloma Cellular Therapies Program and Director of Myeloma and Plasma Cell Pathways at the Dana-Farber Cancer Institute. Learn more about Dr. Nadeem, here.

See More from Thrive Myeloma


Related Programs:

Updates in CAR T-Cell Therapy for Myeloma from ASH 2021

Updates in CAR T-Cell Therapy for Myeloma from ASH 2021

How Could Clinical Trials Fit Into Your Myeloma Treatment Plan?

How Could Clinical Trials Fit Into Your Myeloma Treatment Plan?

An Expert’s Hopeful Outlook on Myeloma Research and Treatment

An Expert’s Hopeful Outlook on Myeloma Research and Treatment 


Transcript:

Katherine:

Personalized medicine for myeloma is slowly becoming more of a reality for patients. Can you provide an update in testing in myeloma? Are there specific markers that you’re looking for when considering patient care?

Dr. Nadeem:

So in multiple myeloma, right now the only targeted therapy that’s in development is looking at venetoclax (Venclexta), and that’s in patients that have the t(11;14) translocation.

So, this has been studied for a while, both as single agent and in combinations and the big BELLINI study, which is looking at it in combination with bortezomib (Velcade) and dexamethasone (Decadron), really has had a lot of buzz over the last few years because there was a toxicity signal with the venetoclax arm.

But now with, again, updated results, etcetera, you’re starting to look to see which are the patients that benefited and which are the patients that didn’t.

And it’s becoming very, very clear that patients that have the t(11;14) translocation tend to benefit tremendously with the combination of venetoclax and bortezomib and dexamethasone. It’s really the patients that don’t have t(11;14) or high BCL2 expression, which is something that they’re also studying, those are the patients that didn’t benefit.

So, really fine tuning that to that particular population and using a combination like that is, I think, an example of where things are headed in myeloma. However, outside of that right now with where things stand, we don’t have targeted therapy to that extent beyond that.

Katherine:

Dr. Nadeem, with the ASH meeting closing out 2021, what are you excited about in myeloma research right now?

Dr. Nadeem:

We’re seeing very impressive results with using quadruplet therapies for newly diagnosed multiple myeloma patents. So, they get a combination of a CD38 monoclonal antibody like daratumamab (Darzalex), and then combining it with our typical agents. So immunomodulatory, drugs, proteasome inhibitors, and steroids. So, an update at this meeting with the phase-2 GRIFFIN trial, which was presented by my colleague Dr. Jacob Laubach, basically giving an update after 24 months of maintenance therapy.

This trial looked at a combination of dara plus RVD, which is lenalidomide, bortezomib, and dexamethasone, with transplant and maintenance, for patients with newly diagnosed myeloma. And what we’ve seen with each update of this study, that the response rates with the quadruplets are significantly better with the triplet. And more notably, we’re seeing very high rates of minimal residual disease negativity in favor of the quadruplet, which usually translates into a greater prognosis for patients.

So, median PFS is still not reached for this particular study, but you can start to see now that the curves are starting to separate and hopefully with longer follow up, we’ll see even a clearer result showing that patients that receive a quadruplet therapy at the newly diagnosed phase of their myeloma therapy benefit tremendously. So, this was a really important update at ASH this year.

Notable News September 2019

September wraps up a big month of cancer awareness. It is the awareness month for childhood cancer, gynecologic cancer, leukemia and lymphoma, ovarian cancer, prostate cancer, and thyroid cancer. Awareness days bring people together to provide educational and fundraising opportunities, and they can help shine a brighter light on the need for funding and research. If you ordered anything from Amazon recently, you may have noticed just how impactful awareness months can be. During the month of September Amazon partnered with the American Childhood Cancer Organization (ACCO) and helped raise awareness by using special packaging designed with the childhood cancer gold ribbon symbol. That kind of exposure can lead to increased funding and support from those who might not otherwise be aware that every three minutes a child is diagnosed with cancer, and it remains the deadliest disease for children in the United States. Learn more at acco.org.
Like leukemia and lymphoma, multiple myeloma is a blood cancer, and while its awareness month is in March, this month there is some promising news for treating the incurable cancer, says biospace.com. The FDA approved the drug Darzalex to be used in combination with other medications for patients newly diagnosed and eligible for autologous stem cell transplant. Studies showed that adding Darzalex to the other medications reduced disease progression or death by 53 percent. More information about the uses of Darzalex can be found here.
Something else to be aware of this month is the potential danger of a popular heartburn medication, reports webmd.com. Ranitidine, known as Zantac, and several generic versions, may pose a cancer risk. The FDA found a cancer causing substance in the drug, and now at least one manufacturer has recalled the drug, and another one has stopped distributing it. It is not yet known why lab testing discovered a carcinogen in the drug, but if you take Zantac, or one of the generic versions, you should probably talk to your doctor, and read more about the findings here.
Of course, it would be ideal if we didn’t have to be aware of cancer at all anymore, and that just may be the case in the future, thanks to a “magic” treatment, says medicalxpress.com. Researchers, using a super computer, have found a molecule that could fix any cancer-related issues in the body. The molecule is promising because, unlike other immunotherapies, it could be sold in pill form, could reach deeper into tissues, and would leave the body faster, reducing negative side effects. Also, it could be used to fight several kinds of cancers including melanoma, breast cancer, lung cancer, lymphoma, and brain cancer. The magic pill still has further development, but the research is moving from the lab to animal testing, so fingers crossed that before long this magic molecule leads to a cure. You can find out more here.
September also hosts Take a Loved One to the Doctor Day, so mark your calendar for next year, and make sure you don’t miss any other important awareness dates. They can be found on the Patient Empowerment Network (PEN) Cancer Awareness Calendar, here.